You are viewing the site in preview mode
Skip to main content
| | |
Group Eb
|
Group Cc
|
χ2
|
P
|
|---|
|
T2d
|
Effective
|
186 (89.0)
|
178 (78.4)
|
8.837
|
0.003
|
| |
Noneffective
|
23 (11.0)
|
49 (21.6)
| | |
|
T3e
|
Effective
|
192 (97.0)
|
195 (90.7)
|
6.874
|
0.009
|
| |
Noneffective
|
6 (3.0%)
|
20 (9.3%)
| | |
|
T4f
|
Effective
|
190 (97.4)
|
203 (97.1)
|
0.036
|
0.850
|
| |
Noneffective
|
5 (2.6)
|
6 (2.9)
| | |
|
T5g
|
Effective
|
189 (97.9)
|
201 (97.6)
|
0.000
|
1.000
|
| |
Noneffective
|
4 (2.1)
|
5 (2.4)
| | |
- aEffective pain reduction is defined as a decrease in pain intensity > 25%, compared with the baseline (T1). Noneffective is defined as a decrease in pain intensity < 25%, compared with the baseline (T1)
- bGroup E (n = 209) was treated with nalbuphine hydrochloride diluted with saline to 1 mg/L.
- cGroup C (n = 228) was administered tramadol hydrochloride diluted with saline to 10 mg/L.
- dT2: after administration at 30 min
- eT3: after administration at 2 h
- fT4: after administration at 4 h
- gT5: after administration at 6 h